Outcomes in curcumin studies. Studies typically use advanced formulations for greatly improved bioavailability.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Saber-Moghaddam 94% 0.06 [0.00-0.93] progression 0/21 8/20 Improvement, RR [CI] Treatment Control Pawar (DB RCT) 82% 0.18 [0.04-0.79] death 2/70 11/70 Ahmadi (DB RCT) 86% 0.14 [0.01-2.65] hosp. 0/30 3/30 Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 86% 0.14 [0.04-0.47] 2/121 22/120 86% improvement Valizadeh (DB RCT) 50% 0.50 [0.18-1.40] death 4/20 8/20 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment 50% 0.50 [0.18-1.40] 4/20 8/20 50% improvement All studies 71% 0.29 [0.13-0.63] 6/141 30/140 71% improvement 4 curcumin COVID-19 studies c19curcumin.com Aug 29, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 3.11 Effect extraction pre-specified Lower Risk Increased Risk
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pawar (DB RCT) 82% 0.18 [0.04-0.79] 2/70 11/70 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 82% 0.18 [0.04-0.79] 2/70 11/70 82% improvement Valizadeh (DB RCT) 50% 0.50 [0.18-1.40] 4/20 8/20 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment 50% 0.50 [0.18-1.40] 4/20 8/20 50% improvement All studies 65% 0.35 [0.13-0.90] 6/90 19/90 65% improvement 2 curcumin COVID-19 mortality results c19curcumin.com Aug 29, 2021 Tau​2 ​ = 0.09; I​2 ​ = 18.2%; Z = 2.18 Lower Risk Increased Risk
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Saber-Moghaddam 45% 0.55 [0.39-0.79] hosp. time 21 (n) 20 (n) Improvement, RR [CI] Treatment Control Ahmadi (DB RCT) 86% 0.14 [0.01-2.65] hosp. 0/30 3/30 Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 46% 0.54 [0.38-0.77] 0/51 3/50 46% improvement All studies 46% 0.54 [0.38-0.77] 0/51 3/50 46% improvement 2 curcumin COVID-19 hospitalization results c19curcumin.com Aug 29, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 3.44 Lower Risk Increased Risk
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Saber-Moghaddam 94% 0.06 [0.00-0.93] progression 0/21 8/20 Improvement, RR [CI] Treatment Control Pawar (DB RCT) 82% 0.18 [0.04-0.79] death 2/70 11/70 Ahmadi (DB RCT) 86% 0.14 [0.01-2.65] hosp. 0/30 3/30 Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 86% 0.14 [0.04-0.47] 2/121 22/120 86% improvement Valizadeh (DB RCT) 50% 0.50 [0.18-1.40] death 4/20 8/20 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment 50% 0.50 [0.18-1.40] 4/20 8/20 50% improvement All studies 71% 0.29 [0.13-0.63] 6/141 30/140 71% improvement 4 curcumin COVID-19 serious outcomes c19curcumin.com Aug 29, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 3.11 Effect extraction pre-specified Lower Risk Increased Risk
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pawar (DB RCT) 82% 0.18 [0.04-0.79] death 2/70 11/70 Improvement, RR [CI] Treatment Control Ahmadi (DB RCT) 86% 0.14 [0.01-2.65] hosp. 0/30 3/30 Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 83% 0.17 [0.05-0.64] 2/100 14/100 83% improvement Valizadeh (DB RCT) 50% 0.50 [0.18-1.40] death 4/20 8/20 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment 50% 0.50 [0.18-1.40] 4/20 8/20 50% improvement All studies 67% 0.33 [0.15-0.75] 6/120 22/120 67% improvement 3 curcumin COVID-19 Randomized Controlled Trials c19curcumin.com Aug 29, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 2.65 Effect extraction pre-specified Lower Risk Increased Risk
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pawar (DB RCT) 82% 0.18 [0.04-0.79] 2/70 11/70 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 82% 0.18 [0.04-0.79] 2/70 11/70 82% improvement Valizadeh (DB RCT) 50% 0.50 [0.18-1.40] 4/20 8/20 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment 50% 0.50 [0.18-1.40] 4/20 8/20 50% improvement All studies 65% 0.35 [0.13-0.90] 6/90 19/90 65% improvement 2 curcumin COVID-19 RCT mortality results c19curcumin.com Aug 29, 2021 Tau​2 ​ = 0.09; I​2 ​ = 18.2%; Z = 2.18 Lower Risk Increased Risk
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Saber-Moghaddam 94% 0.06 [0.00-0.93] progression 0/21 8/20 Improvement, RR [CI] Treatment Control Pawar (DB RCT) 82% 0.18 [0.04-0.79] death 2/70 11/70 Ahmadi (DB RCT) 86% 0.14 [0.01-2.65] hosp. 0/30 3/30 Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 86% 0.14 [0.04-0.47] 2/121 22/120 86% improvement Valizadeh (DB RCT) 50% 0.50 [0.18-1.40] death 4/20 8/20 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Late treatment 50% 0.50 [0.18-1.40] 4/20 8/20 50% improvement All studies 71% 0.29 [0.13-0.63] 6/141 30/140 71% improvement 4 curcumin COVID-19 peer reviewed trials c19curcumin.com Aug 29, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 3.11 Effect extraction pre-specified Lower Risk Increased Risk
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Saber-Moghaddam 94% 0.06 [0.00-0.93] progression 0/21 8/20 Improvement, RR [CI] Treatment Control Saber-Moghaddam 38% 0.62 [0.39-0.96] no recov. 11/21 17/20 Saber-Moghaddam 45% 0.55 [0.39-0.79] hosp. time 21 (n) 20 (n) Pawar (DB RCT) 82% 0.18 [0.04-0.79] death 2/70 11/70 Pawar (DB RCT) 60% 0.40 [0.09-1.75] death 2/15 5/15 Pawar (DB RCT) 91% 0.09 [0.01-1.56] death 0/25 5/25 Pawar (DB RCT) 67% 0.33 [0.01-7.87] death 0/30 1/30 Ahmadi (DB RCT) 86% 0.14 [0.01-2.65] hosp. 0/30 3/30 Ahmadi (DB RCT) 21% 0.79 [0.48-1.31] recov. time 30 (n) 30 (n) Valizadeh (DB RCT) 50% 0.50 [0.18-1.40] death 4/20 8/20 curcumin COVID-19 outcomes c19curcumin.com Aug 29, 2021 Lower Risk Increased Risk
Please send us corrections, updates, or comments.
Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC .
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
